Clinical Cosmetic and Investigational Dermatology,
Journal Year:
2023,
Volume and Issue:
Volume 16, P. 2793 - 2800
Published: Oct. 1, 2023
Cutaneous
lupus
erythematosus
(CLE)
is
a
group
of
diseases
within
the
spectrum
that
primarily
manifests
with
skin
lesions.
Discoid
(DLE)
most
common
subtype
CLE.
Currently,
there
no
specific
medication
available
for
treatment
Here,
we
reported
efficacy
and
safety
upadacitinib,
JAK1
selective
inhibitor,
in
treating
one
DLE
patient
28
weeks.
Upadacitinib
15mg
QD
alone
improved
lesions
significantly,
while
reduction
drug
to
QOD
led
relapse
showed
favorable
this
28-week
period,
except
acne,
which
was
controlled
by
topical
application
benzoyl
peroxide
gel.
In
case,
observed
rapid
sustained
improvement
using
upadacitinib
safety,
provided
opportunity
use
as
an
alternative
therapy
DLE.
Frontiers in Medicine,
Journal Year:
2022,
Volume and Issue:
9
Published: Sept. 23, 2022
Management
of
cutaneous
lupus
erythematosus
(CLE)
involves
a
combination
preventive
measures,
topical
and
systemic
drugs,
fairly
similar
for
the
different
subtypes.
Although
guidelines
exist,
to
date,
no
specific
drugs
have
been
specifically
licensed
CLE.
Antimalarials
remain
first-line
treatment,
but
many
patients
do
not
respond,
making
refractory
challenge
clinicians.
The
choice
alternative
medication
should
be
based
on
effectiveness,
safety
cost.
Most
available
CLE
adapted
from
(SLE)
treatment
existing
literature
is
limited
small
studies
evidence
often
lacks.
As
knowledge
pathogenesis
both
SLE
improving,
promising
new
therapies
are
emerging.
In
this
review,
we
discuss
medications,
focusing
novelties
under
development
Frontiers in Medicine,
Journal Year:
2022,
Volume and Issue:
9
Published: July 11, 2022
Cutaneous
lupus
erythematosus
(CLE)
is
an
autoimmune
disease
that
can
occur
with
or
without
underlying
systemic
(SLE)
and
often
has
a
profoundly
negative
impact
on
patient
quality
of
life.
There
substantial
need
for
new
more
effective
therapies
to
treat
CLE.
CLE
multifactorial
pathogenesis
involves
several
key
immune
cells
pathways,
including
abnormalities
in
innate
(e.g.,
type
1
interferon
pathways)
adaptive
responses
B
T
cell
autoreactivity),
presenting
multiple
opportunities
targeted
do
not
require
immunosuppression.
Here
we
review
emerging
their
efficacy
Anifrolumab
belimumab
have
both
been
approved
the
treatment
SLE
recent
years,
clinical
trial
evidence
suggests
some
forms
may
improve
these
agents.
Therapies
currently
development
are
being
evaluated
CLE-specific
outcome
measures
include
BIIB059
VIB7734,
which
target
plasmacytoid
dendritic
(pDCs),
iberdomide,
cereblon
modulator.
These
novel
all
previously
demonstrated
benefit
Other
molecules
believed
play
role
pathogenesis,
such
as
Janus
kinases
(JAKs),
spleen
tyrosine
kinase
(SYK),
γ
(IFNγ),
IL-12,
IL-23,
trials
skin-specific
outcomes
but
failed
meet
primary
endpoints.
JAAD Case Reports,
Journal Year:
2022,
Volume and Issue:
28, P. 133 - 135
Published: Aug. 28, 2022
Cutaneous
lupus
erythematosus
(CLE)
is
an
autoimmune
disease
that
can
present
in
the
setting
of
multiorgan
system
involvement
such
as
systemic
(SLE)
or
isolated
skin
disease.1
To
date,
no
medication
has
been
specifically
approved
for
treatment
CLE,
and
existing
guidelines
focus
on
topical
agents,
antimalarials,
corticosteroids,
immunosuppressive
drugs.2
However,
recent
advances
understanding
molecular
pathogenesis
CLE
have
opened
possibility
new
modalities.
Clinical Cosmetic and Investigational Dermatology,
Journal Year:
2023,
Volume and Issue:
Volume 16, P. 2793 - 2800
Published: Oct. 1, 2023
Cutaneous
lupus
erythematosus
(CLE)
is
a
group
of
diseases
within
the
spectrum
that
primarily
manifests
with
skin
lesions.
Discoid
(DLE)
most
common
subtype
CLE.
Currently,
there
no
specific
medication
available
for
treatment
Here,
we
reported
efficacy
and
safety
upadacitinib,
JAK1
selective
inhibitor,
in
treating
one
DLE
patient
28
weeks.
Upadacitinib
15mg
QD
alone
improved
lesions
significantly,
while
reduction
drug
to
QOD
led
relapse
showed
favorable
this
28-week
period,
except
acne,
which
was
controlled
by
topical
application
benzoyl
peroxide
gel.
In
case,
observed
rapid
sustained
improvement
using
upadacitinib
safety,
provided
opportunity
use
as
an
alternative
therapy
DLE.
